To support CHART-2 Phase III trial and growth in the US
Cardio3 BioSciences (C3BS), a Belgian clinical stage biotechnology company, plans to open a new US-based manufacturing facility in Rochester, Minnesota.
The 1,000m2 facility will be located in the Minnesota Bio Business Centre and will initially be used to manufacture a cardiovascular product candidate C-Cure for use in CHART-2, a Phase III clinical trial, and its recently acquired CAR T-cell therapies portfolio. It will also serve as a base for the company’s research and clinical collaboration with Mayo Clinic, which is also located in Rochester.
C-Cure is an autologous cellular therapy for the treatment of congestive heart failure that is based on C3BS's Cardiopoiesis platform, initially developed using fundamental research and technology from the Mayo Clinic.
C3BS will receive non-dilutive funding from the Minnesota Department of Employment and Economic Development (DEED) and the Minnesota Job Creation Fund once it completes its investment and staffing goals.